

mondoBIOTECH Holding AG's (SIX:RARE) announces today to have entered into a 3-year investment agreement with GEM Group

Stans, Switzerland – July 17, 2012 - mondoBIOTECH holding AG (SIX: RARE) announces that it has signed an investment agreement with the alternative investment firm, The Global Emerging Markets Group (GEM), whose funds will invest up to CHF 11 million into the Company over the next three years.

This agreement follows the recent announcement where mondoBIOTECH Holding AG ("the Company") was recently granted by its main shareholder, BioPharma Invest AG, the right to purchase up to 30'000'000 shares at a symbolic price; such shares will be thus re-sold by mondoBIOTECH to GEM, by means of a series of transactions throughout the next 36 months, where the Company has the right to raise a committed amount of CHF 7,500,000. Furthermore, additional CHF 3,500,000 may be raised by means of the issuance to GEM of warrant instruments with a tiered strike price up to CHF 0.38.

"We are very pleased to have secured this equity financing agreement with such an important investor, despite the global financial crisis; the capital raised through this deal will put our Company in a position to further strengthen its operation efforts concerning the Medicinal Product Candidate pipeline and the ongoing licensing agreement activities; moreover, such capital endowment will support our business development tasks for potential corporate transactions" commented Ruggero Gramatica, CEO of mondoBIOTECH Holding AG.

Robert Patterson, Chairman of the Board of Directors of mondoBIOTECH Holding AG commented "the biotechnology industry is reshaping its boundaries in respect to research activities and clinical applications and mondoBIOTECH has definitely lined up the right instruments to be an important player in this field and this successful financing will let our Company to endure in its endeavor."

About GEM

Global Emerging Markets Limited, www.gemny.com, was founded in 1991. GEM is a \$3.4b investment group having completed 305 transactions in 65 countries. The firm is an alternative investment group that manages a diverse set of investment vehicles across the world. GEM's funds include: CITIC/GEM Fund; VC Bank/GEM Mena Fund*; Kinderhook; GEM Global Yield Fund; GEM India Advisors, BLOM GEM Opportunities Fund and GEM Brazil PE Fund.

(*GEM exited both its LP and GP stakes in Q1 2010.)

Contact:

Warren P. Baker, III
The Global Emerging Markets Group (GEM)
Email: wbaker@gemny.com
www.gemny.com

About mondoBIOTECH

mondoBIOTECH holding AG (SIX Swiss Exchange ticker symbol: RARE), an independent Swiss biotech company, discovers drugs for patients suffering from rare diseases through its proprietary Search&Match methodology. In Search & Match mondoBIOTECH's scientists combine their unique knowledge of biologically active human peptides with advanced technology solutions delivering medicinal product candidates for rare diseases to licensing partners.

Furthermore, mondoBIOTECH has built and is expanding a continuously growing Community of high-level physicians and researchers who dedicate their life to rare diseases. This Rare Community is composed of biologists, biochemists, physicians, patients and patient advocacy organizations as well as other persons and organizations who share their experiences, know-how, expertise and skills with mondoBIOTECH to reach out to people who will benefit the most from an effective treatment, the patients.

For further information please contact:

mondoBIOTECH holding AG
Maria Teresa D'Antonangelo Bühlmann
Das Kloster
Murgstrasse 18
CH-6370 Stans
Tel.: +41 (0) 840 200 010
Fax: +41 (0) 840 200 011

investor@mondobiotech.com
www.mondobiotech.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning mondoBIOTECH holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of mondoBIOTECH holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. mondoBIOTECH holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.